Hsp90 inhibitors in breast cancer: A systematic review

被引：59

作者：

Zagouri, Flora ^{[1
]}

Sergentanis, Theodoros N. ^{[1
]}

Chrysikos, Dimosthenis ^{[2
]}

Papadimitriou, Christos A. ^{[1
]}

Dimopoulos, Meletios-Athanassios ^{[1
]}

Psaltopoulou, Theodora ^{[3
]}

机构：

[1] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, Athens 11521, Greece

[2] Univ Athens, Sch Med, Hippocrateio Hosp, Propaedeut Surg Dept 1, Athens 11521, Greece

[3] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens 11521, Greece

来源：

BREAST | 2013年 / 22卷 / 05期

关键词：

Breast cancer; Hsp90; inhibitors; Tanespimycin; Alvespimycin; Retaspimycin; HEAT-SHOCK-PROTEIN; PHASE-I TRIAL; TANESPIMYCIN; 17-AAG; ANTITUMOR EFFICACY; DOSE-ESCALATION; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; HEAT-SHOCK-PROTEIN-90; TRASTUZUMAB; HYDROCHLORIDE; COMBINATION;

D O I：

10.1016/j.breast.2013.06.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Pharmacological inhibition of Hsp90 shows great promise in breast cancer treatment. This is the first systematic review to synthesize all available data and to evaluate the efficacy and safety of Hsp90 inhibitors in breast cancer. Methods: This study was performed in accordance with the PRISMA guidelines. Eligible articles were identified by a search of MEDLINE and ClinicalTrials.gov databases, using a predefined combination of the terms "breast", "cancer", "Hsp90", "inhibitors". Results: Overall, 19 articles (190 patients) were eligible. The greatest clinical activity has been observed on the field of HER2-positive metastatic breast cancer. However, accumulating data suggest that Hsp90 inhibitors may play a significant role in the treatment of triple negative and aromatase inhibitor-resistant breast cancer. Conclusion: In the last decade, the development of Hsp90 inhibitors has moved forward rapidly; however, no phase III trials have been conducted and none agent has been approved for use in the clinical practice. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：569 / 578

页数：10

共 50 条

[31] Combination therapies with HSP90 inhibitors against colorectal cancer
Kryeziu, Kushtrim
Bruun, Janie
Guren, Tormod K.
Sveen, Anita
Lothe, Ragnhild A.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1871 (02): : 240 - 247
[32] HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Sidera, Katerina
Patsavoudi, Evangelia
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2014, 9 (01) : 1 - 20
[33] Development of novel hsp90 inhibitors as cancer therapeutics.
Chiosis, G
Rosen, N
Lucas, B
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U46 - U46
[34] Enniatin A Analogues as Novel Hsp90 Inhibitors that Modulate Triple-Negative Breast Cancer
Serwetnyk, Michael A.
Crowley, Vincent M.
Brackett, Christopher M.
Carter, Trever R.
Elahi, Asif
Kommalapati, Vamsi Krishna
Chadli, Ahmed
Blagg, Brian S. J.
ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (12): : 1785 - 1790
[35] Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype?
De Mattos-Arruda, Leticia
Cortes, Javier
BREAST, 2012, 21 (04): : 604 - 607
[36] Interaction of cepharanthine with immobilized heat shock protein 90α (Hsp90α) and screening of Hsp90α inhibitors
Haginaka, Jun
Kitabatake, Tomoko
Hirose, Iyo
Matsunaga, Hisami
Moaddel, Ruin
ANALYTICAL BIOCHEMISTRY, 2013, 434 (01) : 202 - 206
[37] HYPERSENSITIVITY OF HUMAN BREAST CANCER CELLS TO TRIPTOLIDE IN CONJUNCTION WITH HSP90 INHIBITORS AND RADIATION EXPOSURE
Kudryavtsev, V.
Kabakov, A.
ANNALS OF ONCOLOGY, 2011, 22 : 55 - 55
[38] Role of HSP90 in Cancer
Birbo, Bereket
Madu, Elechi E.
Madu, Chikezie O.
Jain, Aayush
Lu, Yi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
[39] HSP90 and the chaperoning of cancer
Whitesell, L
Lindquist, SL
NATURE REVIEWS CANCER, 2005, 5 (10) : 761 - 772
[40] HSP90 and the chaperoning of cancer
Luke Whitesell
Susan L. Lindquist
Nature Reviews Cancer, 2005, 5 : 761 - 772

← 1 2 3 4 5 →